SenesTech, Inc. (SNES) - 10-K Filing Summary
Business Context and Reporting Period
Company: SenesTech, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: SenesTech develops and commercializes fertility control products for rodent population management. The portfolio includes ContraPest (liquid bait) and the Evolve line (soft bait containing cottonseed oil). The company operates as a single segment focused on non-lethal pest control solutions to address regulatory restrictions on traditional rodenticides.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $2.22 million | $1.86 million |
| Gross Profit | $1.39 million | $1.00 million |
| Gross Margin | 62.5% | 54.1% |
| Operating Loss | $(6.51) million | $(6.25) million |
| Net Loss | $(6.38) million | $(6.18) million |
| Cash & Short-Term Investments | $8.57 million | $1.31 million |
| Accumulated Deficit | $(142.48) million | $(136.10) million |
| Notes Payable | $206,000 | $262,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 20% to $2.22 million, driven primarily by the Evolve product line, which grew from $1.23 million (66% of revenue) in 2024 to $1.81 million (81% of revenue) in 2025. ContraPest revenue declined to $0.41 million.
- Margin Expansion: Gross margin improved to 62.5% from 54.1%, attributed to a favorable product mix shift toward Evolve and the resolution of high raw material costs experienced in early 2024.
- Liquidity Improvement: Cash and short-term investments surged from $1.31 million to $8.57 million, fueled by $13.2 million in net proceeds from equity transactions (warrant exercises and ATM sales) during 2025.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose by $0.65 million to $6.20 million, largely due to $0.63 million in legal fees related to an ongoing matter (subsequently settled in March 2026).
Outlook, Risks, and Management Commentary
- Going Concern Status: The company previously faced substantial doubt regarding its ability to continue as a going concern. This doubt was alleviated in 2025 following successful equity raises. Management projects current cash reserves will fund operations through approximately Q2 2027.
- Strategic Focus: Management is prioritizing the scaling of the Evolve product family, expanding e-commerce and retail channels, and reducing manufacturing costs to achieve profitability.
- Legal Resolution: A significant legal contingency involving Liphatech Inc. (alleging trade secret misappropriation) was settled in March 2026, with all litigation dismissed.
- Key Risks:
- Capital Needs: Continued operating losses require additional financing; failure to secure capital could force delays in commercialization.
- Regulatory: While Evolve is a minimum-risk pesticide, state-level registrations are ongoing. ContraPest faces potential stricter testing requirements under evolving EPA policies.
- Market Acceptance: Success depends on convincing pest management professionals to adopt non-lethal fertility control over traditional rodenticides.
Investor Verification Checklist
- Cash Runway: Verify the assumption that current cash ($8.6M) plus anticipated revenue is sufficient to fund operations through Q2 2027 without further dilution.
- Revenue Concentration: Confirm the sustainability of the 24% revenue concentration from a single customer ("Customer D") and the impact of the shift from ContraPest to Evolve.
- Legal Settlement Terms: Review the specific financial terms of the March 2026 settlement with Liphatech Inc. to ensure no material undisclosed liabilities remain.
- Warrant Inducements: Assess the dilution impact of the multiple warrant inducement transactions executed in 2025 and the associated issuance costs.
- Regulatory Expansion: Monitor the progress of state-level registrations for Evolve Mouse (currently 37 states) and Evolve Rat (currently 48 states) to ensure full market access.